×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CADL – candel therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CADL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/13
04:42 pm
cadl
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
Low
Report
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
3/13
04:15 pm
cadl
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Low
Report
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
2/28
07:07 pm
cadl
Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, although long-term gains have benefitted them. [Yahoo! Finance]
High
Report
Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, although long-term gains have benefitted them. [Yahoo! Finance]
2/26
12:29 pm
cadl
Candel Therapeutics, Inc. (NASDAQ: CADL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $20.00 to $25.00. They now have a "buy" rating on the stock.
Medium
Report
Candel Therapeutics, Inc. (NASDAQ: CADL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $20.00 to $25.00. They now have a "buy" rating on the stock.
2/26
08:00 am
cadl
Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Medium
Report
Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
2/25
09:34 am
cadl
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer [Yahoo! Finance]
Medium
Report
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer [Yahoo! Finance]
2/25
08:00 am
cadl
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
High
Report
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
2/20
07:13 am
cadl
Candel Therapeutics, Inc. (NASDAQ: CADL) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $25.00 price target on the stock.
High
Report
Candel Therapeutics, Inc. (NASDAQ: CADL) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $25.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/13
04:30 pm
cadl
Form 10-K Candel Therapeutics, For: Dec 31
Low
Report
Form 10-K Candel Therapeutics, For: Dec 31
3/13
04:15 pm
cadl
Form 8-K Candel Therapeutics, For: Mar 13
Low
Report
Form 8-K Candel Therapeutics, For: Mar 13
2/25
01:36 pm
cadl
Form 4 Candel Therapeutics, For: Feb 21 Filed by: Aguilar Laura K.
Medium
Report
Form 4 Candel Therapeutics, For: Feb 21 Filed by: Aguilar Laura K.
2/25
08:15 am
cadl
Form 8-K Candel Therapeutics, For: Feb 25
High
Report
Form 8-K Candel Therapeutics, For: Feb 25
2/14
05:33 pm
cadl
Form SCHEDULE 13G/A Candel Therapeutics, Filed by: Northpond Ventures, LP
Medium
Report
Form SCHEDULE 13G/A Candel Therapeutics, Filed by: Northpond Ventures, LP
2/14
04:30 pm
cadl
Form 4 Candel Therapeutics, For: Feb 12 Filed by: Schoch Charles
Medium
Report
Form 4 Candel Therapeutics, For: Feb 12 Filed by: Schoch Charles
2/14
04:30 pm
cadl
Form 4 Candel Therapeutics, For: Feb 12 Filed by: Tyagarajan Seshu
Medium
Report
Form 4 Candel Therapeutics, For: Feb 12 Filed by: Tyagarajan Seshu
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: